Hetty E Carraway1, Yazeed Sawalha2, Ivana Gojo3, Min-Jung Lee4, Sunmin Lee4, Yusuke Tomita4, Akira Yuno4, Jackie Greer3, B Douglas Smith3, Keith W Pratz5, Mark J Levis3, Steven D Gore6, Nilanjan Ghosh7, Amy Dezern3, Amanda L Blackford3, Maria R Baer8, Lia Gore9, Richard Piekarz6, Jane B Trepel4, Judith E Karp3. 1. Hematology Oncology Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States. Electronic address: carrawh@ccf.org. 2. Arthur G. James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, United States. 3. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD, United States. 4. Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States. 5. The University of Pennsylvania, Philadelphia, Pennsylvania. 6. Cancer Therapy Evaluation Program (CTEP), National Cancer Institute, NIH, Bethesda, MD, United States. 7. Atrium Health, Carolinas HealthCare System, Charlotte, NC, United States. 8. University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, United States. 9. University of Colorado Cancer Center, Aurora, CO, United States.
Abstract
PURPOSE: Despite advances in immunotherapies, the prognosis for adults with Philadelphia chromosome-negative, newly diagnosed (ND) or relapsed/refractory (R/R) acute lymphoblastic leukemia/acute biphenotypic leukemia (ALL/ABL) remains poor. The benzamide derivative entinostat inhibits histone deacetylase and induces histone hyperacetylation. The purine nucleoside analogue clofarabine is FDA-approved for R/R ALL in children 1-21 years of age. Low doses of clofarabine have been reported to induce DNA hypomethylation. We conducted a phase 1 study of low dose clofarabine with escalating doses of entinostat in adults with ND or R/R ALL/ABL. EXPERIMENTAL DESIGN: Adults ≥60 years with ND ALL/ABL or ≥21 years with R/R ALL/ABL received repeated cycles every 3 weeks of entinostat (4 mg, 6 mg or 8 mg orally days 1 and 8) and clofarabine (10 mg/m2/day IV for 5 days, days 3-7) (Arm A). Adults aged 40-59 years with ND ALL/ABL or age ≥21 years in first relapse received entinostat and clofarabine prior to traditional chemotherapy on day 11 (Arm B). Changes in DNA damage, global protein lysine acetylation, myeloid-derived suppressor cells and monocytes were measured in PBMCs before and during therapy. RESULTS: Twenty-eight patients were treated at three entinostat dose levels with the maximum administered dose being entinostat 8 mg. The regimen was well tolerated with infectious and metabolic derangements more common in the older population versus the younger cohort. There was no severe hyperglycemia and no peripheral neuropathy in this small study. There were 2 deaths (1 sepsis, 1 intracranial bleed). Overall response rate was 32 %; it was 50 % for ND ALL/ABL. Entinostat increased global protein acetylation and inhibited immunosuppressive monocyte subpopulations, while clofarabine induced DNA damage in all cell subsets examined. CONCLUSION: Entinostat plus clofarabine appears to be tolerable and active in older adults with ND ALL/ABL, but less active in R/R patients. Further evaluation of this regimen in ND ALL/ABL appears warranted.
PURPOSE: Despite advances in immunotherapies, the prognosis for adults with Philadelphia chromosome-negative, newly diagnosed (ND) or relapsed/refractory (R/R) acute lymphoblastic leukemia/acute biphenotypic leukemia (ALL/ABL) remains poor. The benzamide derivative entinostat inhibits histone deacetylase and induces histone hyperacetylation. The purine nucleoside analogue clofarabine is FDA-approved for R/R ALL in children 1-21 years of age. Low doses of clofarabine have been reported to induce DNA hypomethylation. We conducted a phase 1 study of low dose clofarabine with escalating doses of entinostat in adults with ND or R/R ALL/ABL. EXPERIMENTAL DESIGN: Adults ≥60 years with ND ALL/ABL or ≥21 years with R/R ALL/ABL received repeated cycles every 3 weeks of entinostat (4 mg, 6 mg or 8 mg orally days 1 and 8) and clofarabine (10 mg/m2/day IV for 5 days, days 3-7) (Arm A). Adults aged 40-59 years with ND ALL/ABL or age ≥21 years in first relapse received entinostat and clofarabine prior to traditional chemotherapy on day 11 (Arm B). Changes in DNA damage, global protein lysine acetylation, myeloid-derived suppressor cells and monocytes were measured in PBMCs before and during therapy. RESULTS: Twenty-eight patients were treated at three entinostat dose levels with the maximum administered dose being entinostat 8 mg. The regimen was well tolerated with infectious and metabolic derangements more common in the older population versus the younger cohort. There was no severe hyperglycemia and no peripheral neuropathy in this small study. There were 2 deaths (1 sepsis, 1 intracranial bleed). Overall response rate was 32 %; it was 50 % for ND ALL/ABL. Entinostat increased global protein acetylation and inhibited immunosuppressive monocyte subpopulations, while clofarabine induced DNA damage in all cell subsets examined. CONCLUSION: Entinostat plus clofarabine appears to be tolerable and active in older adults with ND ALL/ABL, but less active in R/R patients. Further evaluation of this regimen in ND ALL/ABL appears warranted.
Authors: Denise A Yardley; Roohi R Ismail-Khan; Bohuslav Melichar; Mikhail Lichinitser; Pamela N Munster; Pamela M Klein; Scott Cruickshank; Kathy D Miller; Min J Lee; Jane B Trepel Journal: J Clin Oncol Date: 2013-05-06 Impact factor: 44.544
Authors: Elias Jabbour; Johannes Düll; Musa Yilmaz; Joseph D Khoury; Farhad Ravandi; Nitin Jain; Hermann Einsele; Guillermo Garcia-Manero; Marina Konopleva; Nicholas J Short; Philip A Thompson; William Wierda; Naval Daver; Jorge Cortes; Susan O'brien; Hagop Kantarjian; Max S Topp Journal: Am J Hematol Date: 2017-12-23 Impact factor: 10.047
Authors: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: N Gökbuget; M Kelsh; V Chia; A Advani; R Bassan; H Dombret; M Doubek; A K Fielding; S Giebel; V Haddad; D Hoelzer; C Holland; N Ifrah; A Katz; T Maniar; G Martinelli; M Morgades; S O'Brien; J-M Ribera; J M Rowe; A Stein; M Topp; M Wadleigh; H Kantarjian Journal: Blood Cancer J Date: 2016-09-23 Impact factor: 11.037